Sklamberg Quoted in Bloomberg Law on FDA User Fee Review
February 7, 2022
Life Sciences & Healthcare Regulatory partner Howard Sklamberg was quoted in a recent article from Bloomberg Law, “Fast Drug Approvals to Get Lawmaker Focus in FDA Fee Plan Review.” The article discusses the upcoming congressional reauthorization process for the next round of user fee agreements between the FDA and the pharmaceutical companies.
» Read the full article (subscription required).
